About ArQule (NASDAQ:ARQL)
ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ARQL
- CUSIP: 04269E10
- Web: https://www.arqule.com/
Capitalization:- Market Cap: $79 million
- Outstanding Shares: 71,171,000
Average Prices:- 50 Day Moving Avg: $1.13
- 200 Day Moving Avg: $1.12
- 52 Week Range: $0.92 - $1.68
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.78
- P/E Growth: -0.53
Sales & Book Value:- Annual Revenue: $2.41 million
- Price / Sales: 32.78
- Book Value: $0.14 per share
- Price / Book: 7.93
Profitability:- EBITDA: ($26,760,000.00)
- Return on Equity: -213.36%
- Return on Assets: -82.21%
Debt:- Debt-to-Equity Ratio: 1.43%
- Current Ratio: 4.33%
- Quick Ratio: 4.33%
Misc:- Average Volume: 156,277 shs.
- Beta: 1.52
- Short Ratio: 10.48
Frequently Asked Questions for ArQule (NASDAQ:ARQL)
What is ArQule's stock symbol?
ArQule trades on the NASDAQ under the ticker symbol "ARQL."
How were ArQule's earnings last quarter?
ArQule, Inc. (NASDAQ:ARQL) posted its earnings results on Friday, August, 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.01. During the same period in the previous year, the business posted ($0.07) earnings per share. View ArQule's Earnings History.
When will ArQule make its next earnings announcement?
Who are some of ArQule's key competitors?
Some companies that are related to ArQule include Advaxis (ADXS), Palatin Technologies (PTN), Oramed Pharmaceuticals (ORMP), CASI Pharmaceuticals (CASI), OncoMed Pharmaceuticals (OMED), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Zynerba Pharmaceuticals (ZYNE), GTx (GTXI), Regulus Therapeutics (RGLS), Novelion Therapeutics (NVLN), aTyr Pharma (LIFE), Infinity Pharmaceuticals (INFI), Matinas BioPharma Holdings (MTNB), BioLineRx (BLRX), Eiger BioPharmaceuticals (EIGR), CTI BioPharma Corp. (CTIC) and Galectin Therapeutics (GALT).
Who are ArQule's key executives?
ArQule's management team includes the folowing people:
- Patrick J. Zenner, Independent Chairman of the Board
- Peter S. Lawrence, President, Chief Operating Officer
- Paolo Pucci, Chief Executive Officer, Director
- Robert J. Weiskopf, Chief Financial Officer, Treasurer
- Brian Schwartz M.D., Chief Medical Officer
- Timothy C. Barabe, Independent Director
- Susan L. Kelley M.D., Independent Director
- Ronald M. Lindsay Ph.D., Independent Director
- Michael D. Loberg Ph.D., Independent Director
- William G. Messenger D. Min., Independent Director
Who owns ArQule stock?
ArQule's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include
BIOTECHNOLOGY VALUE FUND L P
(19.90%),
BIOTECHNOLOGY VALUE FUND L P
(19.90%) and Curbstone Financial Management Corp (0.15%). Company insiders that own ArQule stock include Michael D Loberg, Paolo Pucci and Patrick J Zenner. View Institutional Ownership Trends for ArQule.
Who bought ArQule stock? Who is buying ArQule stock?
ArQule's stock was bought by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp. Company insiders that have bought ArQule stock in the last two years include Michael D Loberg, Paolo Pucci and Patrick J Zenner. View Insider Buying and Selling for ArQule.
How do I buy ArQule stock?
Shares of ArQule can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ArQule's stock price today?
One share of ArQule stock can currently be purchased for approximately $1.11.
MarketBeat Community Rating for ArQule (NASDAQ ARQL)MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ArQule (NASDAQ:ARQL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Consensus Price Target History for ArQule (NASDAQ:ARQL)
Analysts' Ratings History for ArQule (NASDAQ:ARQL)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/1/2016 | Leerink Swann | Lower Price Target | Market Perform | $3.00 -> $2.50 | N/A |  |
| 12/27/2015 | Royal Bank Of Canada | Upgrade | Buy | | N/A | |
(Data available from 10/22/2015 forward)
Earnings History for ArQule (NASDAQ:ARQL)Earnings History by Quarter for ArQule (NASDAQ ARQL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.11) | | | | | N/A | |
| 8/4/2017 | Q2 2017 | ($0.11) | ($0.10) | | | View | N/A | |
| 5/3/2017 | Q1 2017 | ($0.11) | ($0.11) | | | View | Listen | |
| 3/7/2017 | Q4 2016 | ($0.10) | ($0.10) | $1.20 million | $1.19 million | View | Listen | |
| 11/7/2016 | Q316 | ($0.09) | ($0.08) | $1.10 million | $1.22 million | View | Listen | |
| 8/3/2016 | Q216 | ($0.08) | ($0.07) | $1.13 million | $1.07 million | View | N/A | |
| 5/4/2016 | Q116 | ($0.07) | ($0.08) | $1.63 million | $1.28 million | View | N/A | |
| 2/29/2016 | Q415 | ($0.06) | ($0.05) | $2.40 million | $2.80 million | View | Listen | |
| 11/4/2015 | Q315 | ($0.08) | ($0.04) | $2.60 million | $2.65 million | View | N/A | |
| 8/5/2015 | Q215 | ($0.08) | ($0.06) | $2.50 million | $3.04 million | View | N/A | |
| 5/6/2015 | Q115 | ($0.08) | ($0.07) | $1.98 million | $2.79 million | View | N/A | |
| 3/4/2015 | Q414 | ($0.13) | ($0.06) | $1.90 million | $3.02 million | View | N/A | |
| 11/10/2014 | Q314 | ($0.13) | ($0.10) | $2.20 million | $2.66 million | View | N/A | |
| 8/5/2014 | Q214 | ($0.13) | ($0.10) | $2.43 million | $2.90 million | View | N/A | |
| 5/7/2014 | Q114 | ($0.11) | ($0.11) | $2.29 million | $2.67 million | View | N/A | |
| 3/5/2014 | Q413 | ($0.13) | ($0.10) | $2.27 million | $2.28 million | View | N/A | |
| 10/31/2013 | Q313 | ($0.13) | ($0.10) | $2.77 million | $3.50 million | View | N/A | |
| 7/30/2013 | Q2 2013 | ($0.12) | ($0.11) | $3.84 million | $4.44 million | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.11) | ($0.09) | $3.78 million | $5.66 million | View | N/A | |
| 3/14/2013 | Q4 2012 | ($0.13) | ($0.09) | $5.17 million | $5.14 million | View | N/A | |
| 11/1/2012 | | ($0.07) | ($0.01) | | | View | N/A | |
| 8/2/2012 | | ($0.07) | ($0.01) | | | View | N/A | |
| 5/3/2012 | | ($0.07) | ($0.08) | | | View | N/A | |
| 3/1/2012 | | ($0.09) | $0.07 | | | View | N/A | |
| 11/10/2011 | | ($0.23) | ($0.04) | | | View | N/A | |
| 8/4/2011 | | ($0.19) | ($0.20) | | | View | N/A | |
| 5/5/2011 | | ($0.08) | ($0.03) | | | View | N/A | |
| 3/1/2011 | | ($0.15) | ($0.13) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ArQule (NASDAQ:ARQL)2017 EPS Consensus Estimate: ($0.45)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.10) | ($0.10) | ($0.10) |
| Q2 2017 | 1 | ($0.11) | ($0.11) | ($0.11) |
| Q3 2017 | 1 | ($0.12) | ($0.12) | ($0.12) |
| Q4 2017 | 1 | ($0.12) | ($0.12) | ($0.12) |
(Data provided by Zacks Investment Research)
Dividend History for ArQule (NASDAQ:ARQL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ArQule (NASDAQ:ARQL)Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 61.03%
Insider Trades by Quarter for ArQule (NASDAQ:ARQL)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/7/2017 | Paolo Pucci | CEO | Buy | 1,101 | $1.15 | $1,266.15 | |
| 9/6/2017 | Paolo Pucci | CEO | Buy | 16,397 | $1.15 | $18,856.55 | |
| 9/5/2017 | Paolo Pucci | CEO | Buy | 19,156 | $1.14 | $21,837.84 | |
| 8/29/2017 | Paolo Pucci | CEO | Buy | 300 | $1.05 | $315.00 | |
| 8/28/2017 | Paolo Pucci | CEO | Buy | 2,970 | $1.05 | $3,118.50 | |
| 8/25/2017 | Paolo Pucci | Insider | Buy | 9,492 | $1.05 | $9,966.60 | |
| 12/17/2015 | Michael D Loberg | Director | Buy | 3,719 | $2.16 | $8,033.04 | |
| 12/16/2015 | Michael D Loberg | Director | Buy | 1,231 | $2.14 | $2,634.34 | |
| 12/15/2015 | Paolo Pucci | CEO | Buy | 1,283 | $2.16 | $2,771.28 | |
| 12/11/2015 | Paolo Pucci | CEO | Buy | 1,108 | $2.10 | $2,326.80 | |
| 12/11/2015 | Patrick J Zenner | Director | Buy | 2,300 | $2.15 | $4,945.00 | |
| 12/10/2015 | Paolo Pucci | CEO | Buy | 7,609 | $2.10 | $15,978.90 | |
| 3/11/2015 | Patrick J Zenner | Director | Buy | 10,625 | $2.32 | $24,650.00 | |
| 11/20/2014 | Paolo Pucci | CEO | Buy | 5,000 | $1.26 | $6,300.00 | |
| 11/14/2014 | Patrick J Zenner | Director | Buy | 20,830 | $1.20 | $24,996.00 | |
| 11/13/2014 | Susan L Kelley | Director | Buy | 50,000 | $1.20 | $60,000.00 | |
| 9/4/2014 | Paolo Pucci | CEO | Buy | 5,000 | $1.31 | $6,550.00 | |
| 5/23/2014 | Paolo Pucci | CEO | Buy | 5,000 | $1.40 | $7,000.00 | |
| 5/20/2014 | Paolo Pucci | CEO | Buy | 5,000 | $1.42 | $7,100.00 | |
| 3/17/2014 | Patrick Zenner | Director | Buy | 4,715 | $2.12 | $9,995.80 | |
| 3/13/2014 | Paolo Pucci | CEO | Buy | 10,000 | $2.10 | $21,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for ArQule (NASDAQ:ARQL)
Latest Headlines for ArQule (NASDAQ:ARQL)
| Source: |
|
Loading headlines, please wait.
ArQule (ARQL) Chart for Sunday, October, 22, 2017
